GoodRx Holdings, Inc. (NASDAQ: GDRX) saw its stock price surge 5.98% in after-hours trading on Wednesday following the release of its first-quarter 2025 financial results. The leading platform for medication savings in the U.S. reported in-line revenue and beat expectations on adjusted EBITDA, while maintaining its full-year revenue guidance and raising its adjusted EBITDA outlook.

For the first quarter of 2025, GoodRx reported revenue of $203 million, aligning with the IBES estimate of $202.2 million. The company's adjusted EBITDA came in at $69.8 million, surpassing the IBES estimate of $67 million. Notably, the adjusted EBITDA margin improved to 34.4%, demonstrating the company's ability to enhance profitability.

Investors were particularly encouraged by GoodRx's outlook for the remainder of 2025. The company maintained its full-year revenue guidance range of $810 to $840 million, representing a 2% to 6% growth compared to 2024. Additionally, GoodRx raised its adjusted EBITDA expectations for the full year to between $273 and $287 million, indicating a 5% to 10% growth over 2024. The company also provided a positive outlook for the second quarter, expecting revenue to increase sequentially from the first quarter's $203 million, with an adjusted EBITDA margin similar to Q1. This strong performance and optimistic forecast likely contributed to the stock's after-hours rally.